ÌÇÐÄvlog

[Skip to Navigation]
Sign In

Year

Day

October 31, 2024
Original Investigation

Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online October 31, 2024. doi:10.1001/jamaoncol.2024.4361

This randomized clinical trial evaluates the combination of veliparib and temozolomide in treating glioblastoma.

Survival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis

Abstract Full Text
open access
JAMA Oncol. Published online October 31, 2024. doi:10.1001/jamaoncol.2024.4890

This cohort study evaluates the survival outcomes of currently smoking patients with cancer who entered into a smoking cessation treatment program based on the time between diagnosis and program entry.

Viewpoint

Effects of the Oncology Industrial Complex on Academic Cancer Centers

Abstract Full Text
JAMA Oncol. Published online October 31, 2024. doi:10.1001/jamaoncol.2024.4876

This Viewpoint outlines the missions of academic cancer centers and how they are being affected by the oncology industrial complex along with challenges and suggestions for an aligned way forward.

Poetry and Oncology

metastatic

Abstract Full Text
JAMA Oncol. Published online October 31, 2024. doi:10.1001/jamaoncol.2024.4899
Comment & Response

Expanding Clinical Trial Accessibility in the Digital Era With Telemedicine

Abstract Full Text
JAMA Oncol. Published online October 31, 2024. doi:10.1001/jamaoncol.2024.4908

Expanding Clinical Trial Accessibility in the Digital Era With Telemedicine—Reply

Abstract Full Text
JAMA Oncol. Published online October 31, 2024. doi:10.1001/jamaoncol.2024.4911
Correction

Errors in Figure 3

Abstract Full Text
free access
JAMA Oncol. Published online October 31, 2024. doi:10.1001/jamaoncol.2024.5240
October 24, 2024
Original Investigation

Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma: A Phase 2 Nonrandomized Clinical Trial

Abstract Full Text
JAMA Oncol. Published online October 24, 2024. doi:10.1001/jamaoncol.2024.4019

This phase 2 nonrandomized clinical trial assesses the efficacy and safety of dual immune checkpoint inhibition in patients with aggressive thyroid carcinoma.

Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial

Abstract Full Text
open access has audio
JAMA Oncol. Published online October 24, 2024. doi:10.1001/jamaoncol.2024.4729

This nonrandomized clinical trial examines whether matched-targeted therapy based on tumor mutation status with a PD-L1 inhibitor is associated with improved overall survival among patients with anaplastic thyroid carcinoma.

JAMA Oncology Clinical Challenge

Hairy Kidneys and Sclerotic Bone Lesions

Abstract Full Text
has active quiz
JAMA Oncol. Published online October 24, 2024. doi:10.1001/jamaoncol.2024.4748

A 72-year-old man with a history of polycythemia vera (positive for JAK2 V617F) presented with several months of functional decline and weight loss. An 18F-fluorodeoxyglucose positron emission tomography/computed tomography showed soft tissue infiltrates and sclerosis of the perirenal spaces with fluorodeoxyglucose uptake. What is your diagnosis?

Viewpoint

Cancer Drug Access and Innovation Under the Inflation Reduction Act—A Balancing Act

Abstract Full Text
JAMA Oncol. Published online October 24, 2024. doi:10.1001/jamaoncol.2024.4745

This Viewpoint explores whether the Inflation Reduction Act’s provisions and price negotiations could affect investment in trials of new oncology therapies or indications.

Editorial

Impacts of Immunotherapy on Patients With Aggressive Thyroid Carcinomas

Abstract Full Text
JAMA Oncol. Published online October 24, 2024. doi:10.1001/jamaoncol.2024.4202
Comment & Response

Chemoimmunotherapy in Older Adults With Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. Published online October 24, 2024. doi:10.1001/jamaoncol.2024.4754

Chemoimmunotherapy in Older Adults With Non–Small Cell Lung Cancer—Reply

Abstract Full Text
JAMA Oncol. Published online October 24, 2024. doi:10.1001/jamaoncol.2024.4757
October 17, 2024
Original Investigation

Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. Published online October 17, 2024. doi:10.1001/jamaoncol.2024.4381

This randomized clinical trial evaluates whether the combination of lenvatinib plus ifosfamide and etoposide improves outcomes in children and young adults with relapsed osteosarcoma.

Brief Report

Diet Quality, Dietary Inflammatory Potential, and Risk of Prostate Cancer Grade Reclassification

Abstract Full Text
JAMA Oncol. Published online October 17, 2024. doi:10.1001/jamaoncol.2024.4406

This cohort study examines whether there is an association of diet quality and dietary inflammatory potential with prostate cancer grade reclassification in men with grade group 1 disease undergoing active surveillance.

Comment & Response

Considerations of Lay Health Worker Intervention Among Patients With Advanced Cancer

Abstract Full Text
JAMA Oncol. Published online October 17, 2024. doi:10.1001/jamaoncol.2024.4575

Considerations of Lay Health Worker Intervention Among Patients With Advanced Cancer—Reply

Abstract Full Text
JAMA Oncol. Published online October 17, 2024. doi:10.1001/jamaoncol.2024.4578

Comment on Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer

Abstract Full Text
JAMA Oncol. Published online October 17, 2024. doi:10.1001/jamaoncol.2024.4581

Comment on Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer—Reply

Abstract Full Text
JAMA Oncol. Published online October 17, 2024. doi:10.1001/jamaoncol.2024.4584
Correction

Error in Byline

Abstract Full Text
free access
JAMA Oncol. Published online October 17, 2024. doi:10.1001/jamaoncol.2024.5097
October 10, 2024
Original Investigation

Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification

Abstract Full Text
open access
JAMA Oncol. Published online October 10, 2024. doi:10.1001/jamaoncol.2024.4354

This diagnostic study examines the formation of the ninth version of the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) tumor-node-metastasis (TNM) staging system.

Research Letter

Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories

Abstract Full Text
free access
JAMA Oncol. Published online October 10, 2024. doi:10.1001/jamaoncol.2024.4412

This cross-sectional study uses a large natural language processing model to examine unmet medical and social needs based on cancer-related fundraising stories in the US.

JAMA Oncology Diagnostic Test Interpretation

Endometrial Cancer Classification and Management in the Molecular Subtyping Era

Abstract Full Text
has active quiz
JAMA Oncol. Published online October 10, 2024. doi:10.1001/jamaoncol.2024.4376

A 65-year-old woman presented with a 6-month history of postmenopausal vaginal bleeding, and endometrial biopsy showed grade 2 endometrioid adenocarcinoma. What would you do next?

Viewpoint

Implementing Resource-Stratified Guidelines in LMICs—More Issues Than Solutions

Abstract Full Text
JAMA Oncol. Published online October 10, 2024. doi:10.1001/jamaoncol.2024.4351

This Viewpoint discusses the importance of formulating more stable local treatment guidelines because international guidelines and even resource-stratified guidelines may not be as applicable in low- to middle-income countries.

Invited Commentary

Staging and Prognosis of Nasopharyngeal Cancer: The Time for Change Is Now

Abstract Full Text
JAMA Oncol. Published online October 10, 2024. doi:10.1001/jamaoncol.2024.4201
Comment & Response

Differences in Sentinel Node Biopsy and Targeted Axillary Dissection Following Neoadjuvant Chemotherapy

Abstract Full Text
JAMA Oncol. Published online October 10, 2024. doi:10.1001/jamaoncol.2024.4569

Differences in Sentinel Node Biopsy and Targeted Axillary Dissection Following Neoadjuvant Chemotherapy—Reply

Abstract Full Text
JAMA Oncol. Published online October 10, 2024. doi:10.1001/jamaoncol.2024.4572
October 3, 2024
Original Investigation

Fracture Risk Prediction Using the Fracture Risk Assessment Tool in Individuals With Cancer

Abstract Full Text
JAMA Oncol. Published online October 3, 2024. doi:10.1001/jamaoncol.2024.4318

This retrospective cohort study assesses the prognostic value of the Fracture Risk Assessment Tool (FRAX) for incident fractures in patients with cancer.

Brief Report

Prevalence and Factors Associated With Prostate Cancer Among Transgender Women

Abstract Full Text
JAMA Oncol. Published online October 3, 2024. doi:10.1001/jamaoncol.2024.4335

This cohort study evaluates the prevalence of prostate cancer among transgender women in the US and examines factors associated with prostate cancer, biochemical recurrence, and bone metastases in transgender patients.

Research Letter

Mismatch Repair and Microsatellite Testing for Individuals With Colorectal Cancer

Abstract Full Text
JAMA Oncol. Published online October 3, 2024. doi:10.1001/jamaoncol.2024.4342

This cohort study examines the institution-level and patient-level factors associated with mismatch repair and microsatellite testing for individuals with colorectal cancer.

Special Communication

Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs

Abstract Full Text
has active quiz
JAMA Oncol. Published online October 3, 2024. doi:10.1001/jamaoncol.2024.4330

This study provides a guidance document to educate clinicians and patients on biomarkers informing prognosis and treatment in unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).

Invited Commentary

Moving the Needle on Equity in Prostate Cancer

Abstract Full Text
JAMA Oncol. Published online October 3, 2024. doi:10.1001/jamaoncol.2024.3927
Comment & Response

Ensuring Safety and Consistency in Artificial Intelligence Chatbot Responses

Abstract Full Text
JAMA Oncol. Published online October 3, 2024. doi:10.1001/jamaoncol.2024.4324

Ensuring Safety and Consistency in Artificial Intelligence Chatbot Responses—Reply

Abstract Full Text
JAMA Oncol. Published online October 3, 2024. doi:10.1001/jamaoncol.2024.4327
Correction

Error in Figure 1

Abstract Full Text
free access
JAMA Oncol. Published online October 3, 2024. doi:10.1001/jamaoncol.2024.4797
×